Alaunos Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Alaunos Therapeutics, Inc. (TCRT), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on April 11, 2025. The filing details a material definitive agreement entered into on the same date regarding a private equity offering.
Key Financial Metrics and Transaction Details
The Company completed a private offering of Series A-1 Convertible Preferred Stock to Watermill Asset Management. Key terms include:
- Aggregate Purchase Price: $500,000
- Shares Issued: 500 shares of Series A-1 Convertible Preferred Stock (1,000 shares designated)
- Price Per Share: $1,000 stated value
- Dividend Rate: 10% per annum, payable in shares of Series A-1 Preferred Stock
- Conversion Price: Initial fixed price of $2.76 per share of Common Stock
- Voting Rights: 1:1 ratio on an as-converted basis alongside Common Stock
The filing does not provide specific data on the Company's overall revenue, profit, cash flow, margins, or total debt levels as of the reporting date.
Material Changes
The primary material change is the issuance of new equity securities and the creation of a new class of preferred stock. This transaction increases the Company's capital base by $500,000 and alters the capital structure by introducing a convertible instrument with a 10% dividend obligation.
Outlook, Risks, and Unusual Items
The securities were sold in a private placement under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D and are not registered. Consequently, these securities may not be offered or sold in the United States absent registration or an applicable exemption. The filing incorporates the full Subscription Agreement and Certificate of Designation by reference for complete terms.
Investor Verification Checklist
- Verify the full text of the Subscription Agreement (Exhibit 10.1) for additional covenants or restrictions.
- Review the Certificate of Designation (Exhibit 3.1) for specific conversion adjustment mechanisms and liquidation preferences.
- Confirm the impact of the 10% dividend obligation on future cash flow requirements.
- Assess the dilution impact on existing common shareholders upon conversion at the $2.76 price.